An open-label randomized controlled trial of curcumin versus standard dose of omeprazole in treatment of gastroesophageal reflux disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230330010

Enrollment

170

Registered

2023-03-30

Start date

2021-09-20

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

GERD symptom at entry compare to after 4 weeks of treatment between curcumin and omeprazole GERD, curcumin, omeprazole

Interventions

curcumin 500 mg oral four times daily continue for 4 weeks ,omeprazole 20 mg per day oral continue for 4 weeks

Active Comparator Drug,Active Comparator Drug

curcumin ,omeprazole

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: patients who were diagnosed with gastroesophageal reflux disease (GERD) according to the Thailand GERD guideline 2020

Exclusion criteria

Exclusion criteria: 1 patients presenting with alarm features such as dysphagia, gastrointestinal bleeding, anemia, involuntary weight loss, recurrent vomiting and odynophagia 2 pregnant women or women who planned to become pregnant during the study 3 patients previously diagnosed with esophageal stricture, esophageal cancer, irritable bowel diseases, hepatobiliary tract obstruction, refractory GERD 4 allergy to omeprazole or curcumin 5 unable to read and write in Thai language

Design outcomes

Primary

Measure	Time frame
symptom of GERD 4 weeks after treatment number of patient who symptom improve, GSAS	—

Secondary

Measure	Time frame
duration of symptom improvement 4 weeks after treatment days	—

Countries

Thailand

Contacts

Public ContactOnsinee Wittanakorn

Phramongkutklao Hospital

onsinee.wit@gmail.com0811555522

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026